Upbeat On Injectables, Aurobindo Hiking Capacities

Acquisition In Emerging Markets Possible

Aurobindo expects revenues from injectables to increase to $650-700m over the next three years as its Vizag plant gets commissioned in a year’s time. Apart from seeking organic growth, the company is keeping an eye out for acquisitions in emerging markets though big-ticket ones are ruled out.

Injection
Several Indian Companies Are Focused On The Global Injectables Market • Source: Shutterstock

Aurobindo Pharma Limited expects injectables’ revenues to increase to $650-700m over three years from the current $380m with contribution from Europe and emerging markets growing even as injectable margins in the US see a possible decline due to increased competition.

A new plant in Vizag is expected to be commissioned in around a year, with supply directed to Europe and...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Business

More from Scrip